Nasdaq

Qiagen Gets U.S. Regulatory Clearance For QIAstat-Dx Gastrointestinal Panel Tests

(RTTNews) - Qiagen (QGEN) announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. The clearance by the U.S. Food and Drug ...
Business Insider

QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal ...
Business Wire

Applied BioCode’s Syndromic Gastrointestinal Pathogen Panel Approved by the FDA on BioCode® MDx-3000 System

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced that it has received U.S. Food and Drug Administration 510(k) clearance for BioCode Gastrointestinal Pathogen Panel (GPP) with high ...
Business Wire

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx ...